An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China
A CHEERS-compliant article

Bin Wu, PhD, Maobai Liu, PhD, Te Li, PharmD, Houwen Lin, PhD, Hua Zhong, PhD

Abstract
Background: The aim of the study was to test the cost-effectiveness of dasatinib compared to high-dose imatinib and nilotinib in Chinese patients who were diagnosed with imatinib-resistant chronic myeloid leukemia in the chronic phase (CML-CP).

Methods: A Markov model combined with clinical effectiveness, utility, and cost data was used. The sensitivity analyses were conducted to determine the robustness of the model outcomes. The impact of patient assistance programs (PAPs) was assessed.

Results: Treatment with dasatinib is expected to produce 3.65, 0.59, and 0.15 more quality-adjusted life years (QALYs) in comparison with high-dose imatinib (600 and 800 mg) and nilotinib, respectively. When a PAP was available, dasatinib yielded an incremental cost of $16,417 per QALY compared to imatinib (600 mg) and was cost-saving compared to imatinib (800 mg) and nilotinib.

Conclusion: When PAP is available in the Chinese setting, dasatinib is likely to be a cost-effective strategy for patients with CML-CP standard-dose imatinib resistance. The results should be carefully explained due to the assumptions and limitations used in the study.

Abbreviations: AEs = adverse events, AP = accelerated phase, BC = blast crisis, CCyR = complete cytogenetic response, CML = chronic myeloid leukemia, CP = chronic phase, GDP = gross domestic product, ICER = incremental cost-effectiveness ratio, LY = life years, NR = no response to treatment, OS = overall survival, PAP = patient assistance programme, PCyR = partial cytogenetic response, PFS = progression-free survival, PFT = post-failure treatments, QALY = quality-adjusted life-year, TKI = tyrosine kinase inhibitor.

Keywords: chronic myeloid leukemia, cost-effectiveness, dasatinib, Markov model

1. Introduction

Chronic myeloid leukemia (CML) is the third most common type of leukemia worldwide. Worldwide, the average annual incidence of CML is 0.6 to 2 new cases per 100,000 people (median age: 53 years). In China, 5000 to 8000 new cases are diagnosed annually, and the median age is much younger (40 years). The natural course of CML consists of the following 3 gradually progressive phases: (1) chronic phase (CP), (2) accelerated phase (AP), and (3) blast crisis (BC). The CP is the benign phase of CML that is characterized by mild symptoms, including fatigue and weight loss. The advanced phases (AP and BC) are associated with disease progression and a much poorer prognosis. Most people (approximately 90%) are diagnosed during the CP.

Imatinib was the first TKI utilized for the treatment of CML and is widely prescribed. According to the International Randomized Study of Interferon and STI571 (IRIS) study, patients randomized to receive imatinib demonstrated an 85% overall survival (OS) rate (8 year data) and 0.9%, 0.5%, 0%, and 0.4% annual rates of progression to AP or BC in years 4 to 8, respectively, after imatinib therapy onset. Imatinib is the first-line treatment recommendation for newly diagnosed CML patients. However, nearly 40% of patients discontinue imatinib after 3 years due to the absence of efficacy (primary resistance), loss of previously obtained responses (acquired resistance), and/or intolerance to therapy. High-dose imatinib (600 or 800 mg per day) and second-generation TKIs, including dasatinib and nilotinib, have been used to treat imatinib-resistant CML. According to economic analyses, dasatinib and nilotinib offer good value-for-money for CML patients who experience imatinib failure in Sweden, the United Kingdom, and Thailand.
for decision making in China because of dealing with economic data transferability[9] is still in challenge due to different epidemiological variables, clinical practice, health resource consumption associated with CML, prices of TKIs, and their preferential policies in different regions. As a BRIC (Brazil, Russia, India, and China) country with a huge population and medium incomes, Chinese decision makers face the question of whether second-generation TKIs should be covered by insurance. The results of the current analysis also might be a reference for other East Asian regions and BRIC countries.

In this study, we examined whether dasatinib (100mg) and nilotinib (800mg) are cost-effective treatments for CML-CP patients who are resistant to normal-dose imatinib in China.

2. Patients and methods

2.1. Model structure

A Markov cost-effectiveness model was developed to model the lifetime disease progression in patients with CML-CP and failure of normal-dose imatinib (Fig. 1). In the Markov model, the modeling diseases are structured around a set of mutually exclusive and collectively exhaustive health states, and a hypothetical individual must be in only 1 state in any cycle. The average number of cycles that individuals reside in each state can be used in conjunction with state values (e.g., life-years, health-related quality-of-life, and cost) to estimate life expectancy, quality-adjusted life expectancy, and expected costs.[10] The model consists of the following 3 health states: (1) stable disease, (2) progressed disease, and (3) death; the model uses monthly cycles with probabilities for the likelihood of a health state transition. All the patients were assumed to start with one of the following treatments for CML-CP: (1) nilotinib 800mg daily (nilotinib strategy), (2) dasatinib 100mg daily (dasatinib strategy), (3) imatinib 600mg daily (imatinib 600mg strategy), or (4) imatinib 800mg daily (imatinib 800mg strategy). The following 4 responses to medical treatment after an initial 3-month treatment period were used to predict disease progression: (1) no response to treatment (NR); (2) achieved a complete hematologic response (CHR); (3) achieved a partial cytogenetic response (PCyR); or (4) achieved a complete cytogenetic response (CCyR). It was assumed that when patients failed the therapy (i.e., the patients were categorized as "no response") or the disease progressed and they discontinued treatment that all patients received similar postfailure treatments (PFT) according to an expert’s opinion. The patients included in the model at baseline reflected the normal clinical characteristics (such as age) of the Chinese patients.[21] The model was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA).

Life expectancy (life years, LYS), quality-adjusted life years (QALYs), and the associated direct medical costs were the primary outcomes. Incremental cost-effectiveness ratios (ICERs) were calculated and expressed as cost per additional QALY gained. Future costs and QALYs were annually discounted at 3%. This economic study was based on a literature review and model techniques, and did not require approval by the institutional Research Ethics Board.

2.2. Clinical data

Based on the 2 small confirmatory clinical trials, the similar efficacy of TKIs was found between Chinese and other populations,[11,12] which enrolled 119 patients receiving dasatinib 100mg daily and 23 patients receiving nilotinib 800mg daily treatment, respectively. Thus, the current analysis would assume the clinical data from abroad pivotal clinical trials[13–16] would be same with the Chinese setting. The efficacy data for imatinib (600mg), imatinib (800mg), nilotinib, and dasatinib used in the model achieved initial response rates within 24 months (Table 1), including CCyR, PCyR, and CHR, the known surrogates for progression-free survival (PFS). Although these efficacy data were obtained from different trials, we assumed they were comparable as previous reports had done[6–8] because of their similar inclusion and exclusion criteria and the recommendation of clinical guidelines used them as the evidence source.[17,18] We would check this assumption in the sensitivity analysis. The PFS data were obtained from the CA180-034 study, where 670 patients with CML-CP and imatinib failure received dasatinib at doses of 100mg once daily, 50mg twice daily, 140mg once daily, or 70mg twice daily; the estimated 6-year protocol-defined PFS rates for the different doses of dasatinib were 49%, 51%, 40%, and 47%, respectively.[13] The Kaplan–Meier survival data for PFS in patients with CCyR, PCyR, and CHR was fitted to

Table 1

| Parameter | NR | CHR | PCyR | CCyR | Source |
|-----------|----|-----|------|------|--------|
| Response of treatment | | | | | |
| 600 mg-imatinib | 56.4% | 15.4% | 26.2% | 0.0% | [15] |
| 800 mg-imatinib | 32.1% | 13.3% | 14.1% | 40.5% | [16] |
| Nilotinib 800 mg | 6.0% | 35.0% | 18.0% | 41.0% | [15] |
| Dasatinib 400 mg | 8.1% | 33.1% | 15.3% | 45.9% | [14] |

CCyR = complete cytogenetic response, CHR = complete hematologic response, NR = no response, PCyR = partial cytogenetic response, PFS = progression-free survival.

Lambda = 0.149, Gamma = 0.5856

Figure 1. General process for second-line treatments in patients with imatinib-resistant or intolerant CML. The risk of disease progression depends on the underlying treatment strategy and treatment response. CCyR = complete cytogenetic response, CML = chronic myeloid leukemia, CHR = complete hematologic response, PCyR = partial cytogenetic response.
the Weibull distribution, where the lambda gamma parameters were measured. The risk for transitioning from CP to advanced phases was estimated from the Weibull survival model.\(^{[19]}\) It was assumed that the prognosis was dependent on the treatment response regardless of the specific TKI prescribed.\(^{[20–22]}\)

After the disease progressed to the advanced phase, the median OS was 12 months.\(^{[23]}\) The survival time spent in the AP and BC phases was assumed to be independent of treatment. The unspecified mortality in the CP was modeled as a function of age and sex from the current Chinese life-table.\(^{[24]}\)

The data related to adverse events (AEs) were extracted from trials.\(^{[13–16]}\) We analyzed the frequency of AEs over time. Because nearly 95% of AEs occurred during the first year (not more than a 5% increase during the second year),\(^{[25]}\) we decided to quantify AEs only during the first year of TKI therapy in our model. Furthermore, we identified only grade 3/4 AEs occurring in 10% or more of the patients for model input based on a Chinese hematologist’s opinion.\(^{[27]}\)

### 2.3. Cost and utility

Chinese clinical practices related to CML were validated from interviews with 2 Chinese clinical hematologists at the same facility. “Cost” is from the perspective of the Chinese health care system. Direct medical costs (Table 2), such as pharmaceuticals and laboratory tests, as well as inpatient costs were obtained from official Chinese sources.\(^{[26]}\) All the costs were converted into 2015 US dollars (CYN 6.20 = US $1.00).

Costs for dasatinib, nilotinib, and imatinib were added for each month that a patient remained in the CP. The drug dosages were based on trials from which we sourced the initial responses (Table 1). Because TKIs are administered orally, no administration costs would be incurred. The monthly costs associated with follow-up visits and SAE management in CML-CP patients were estimated from Chinese clinical experts. After disease progression, the monthly cost of PFT was obtained via medical chart reviews from local hospitals.

Utility scores published in the literature were included in the current analysis (Table 2). The impact of the SAEs on health utility was also captured in the model, where the utility estimates for SAEs were assumed to be a 5% decrement because no reference was identified.

### 2.4. Sensitivity analyses

Because it can be challenging for patients to afford TKIs in health resource-limited settings, a patient assistance program (PAP) would possibly be introduced to make TKIs available to eligible patients. Currently, CML patients in a PAP would pay for 3 months of TKIs and receive 9 months of donations every year. Therefore, the scenario analyses assessed the impact of dasatinib PAP for targeted therapy.

Sensitivity analyses included univariate and probabilistic sensitivity analyses. A wide range of univariate sensitivity analyses were conducted to test the robustness of the model outcomes by varying effectiveness, utility, and cost parameters. Probabilistic sensitivity analyses were conducted using a Monte Carlo simulation. One thousand simulations of the model were run in the probabilistic sensitivity analysis, which adopted probabilities, proportions, and utilities following beta distributions, non-drug costs following gamma distributions, and dose intensities (normal distributions).

We used $3 \times$ the per capita gross domestic product (GDP) of China in 2014 as the cost-effective threshold according to WHO recommendations.\(^{[27–29]}\)

### 3. Results

#### 3.1. Base-case analyses

The model-derived PFS probabilities were calculated according to the initial responses during the time from the first month to the 48th month, and the simulated PFS curves satisfactorily matched those from the clinical trial (Fig. 2). The goodness-of-fit test showed that the adjusted $R^2$ values for CHR, PCyR, and CCyR were 0.97, 0.94, and 0.77, respectively.

Dasatinib treatment provided more health benefits compared to high-dose imatinib and nilotinib. Additional PFS times for dasatinib (400 mg) versus imatinib (600 mg), imatinib (800 mg), and nilotinib (800 mg) were 3.96, 0.72, and 0.22 years, respectively, and the LYS increased by 5.89, 0.71, and 0.22 years,

---

**Table 2**

| Parameters | Unit cost | Range | Source |
| --- | --- | --- | --- |
| Resource use per month, US $ | 1542 | 771–1542\(^*\) | Local charge |
| Imatinib 600 mg | 2056 | 1028–2056\(^*\) | Local charge |
| Nilotinib 800 mg | 1579 | 789–1579\(^*\) | Local charge |
| Dasatinib 100 mg | 1276 | 638–1276\(^*\) | Local charge |
| Follow-up visiting for responders | 141 | 59–225 | Expert opinion |
| Follow-up visiting for nonresponders | 320 | 199–609 | Expert opinion |
| Postfailure treatment\(^†\) | 950 | 443–885 | Expert opinion |
| Management of SAEs in imatinib 600 mg arm\(^\ddagger\) | 297 | 208–595 | Expert opinion |
| Management of SAEs in imatinib 800 mg arm\(^\ddagger\) | 297 | 208–595 | Expert opinion |
| Management of SAEs in nilotinib 800 mg arm\(^\ddagger\) | 497 | 497–995 | Expert opinion |
| Management of SAEs in dasatinib 100 mg arm\(^\ddagger\) | 372 | 372–744 | Expert opinion |
| Utility score | 0.84 | 0.82–0.86 | [\(^{27}\) ] |
| CML-CP with response | 0.66 | 0.63–0.68 | [\(^{27}\) ] |
| CML-CP with no response | 0.21 | 0.19–0.24 | [\(^{27}\) ] |

\(\text{The range was assumed for a 1-way sensitivity analysis.}\)

\(\text{The cost was estimated based on expert opinion; 50% of patients received chemotherapy; 30% received bone marrow transplantation; and the remaining patients received palliative care.}\)

\(\text{The costs related to the management of SAEs were derived from hematologists who determined the costs by multiplying the unit cost of treating SAEs and the probabilities of SAEs from trials.}\)\(^{[13–16]}\)
respectively. The additional QALYs gained of dasatinib were ranged from 0.15 against nilotinib to 3.65 against imatinib (600 mg) (Table 3). The increased cost of dasatinib over imatinib (600 mg) without or with the PAP was $215,084 and $59,859, which yielded ICERs of $58,989 and $16,417/QALY, respectively. Compared to imatinib (800mg) and nilotinib, dasatinib treatment saved money and was effective (Fig. 3).

### 3.2. Sensitivity analyses

Because dasatinib and nilotinib have been recommended for the management of patients with imatinib failure and PAP was available in the Chinese setting, a 1-way sensitivity analysis for dasatinib versus nilotinib with PAP was performed. Dasatinib was more effective than nilotinib according to most of the sensitivity analyses (Table 4). The initial treatment response has a substantial impact. If the CCyR of dasatinib decreased to 39.5% or the CCyR of nilotinib increased to 44%, the dasatinib strategy would become less effective.

Based on the probabilistic sensitivity analyses, the cost-effectiveness acceptability curves showed that dasatinib without and with PAP had a 0 and 0.90 probability, respectively, of being cost-effective at a willingness-to-pay threshold of $22,455/QALY (Fig. 4).

### 4. Discussion

We evaluated the cost-effectiveness of 4 different treatments in Chinese CML patients who were resistant to standard-dose imatinib. Our findings identified dasatinib as the dominant strategy in terms of incremental costs per additional QALY gained. This finding may be due to both the considerable survival and quality of life advantages offered by dasatinib. The ICERs of dasatinib versus the imatinib (600 mg) strategy ranged from $61,429/QALY without PAP to $18,021/QALY with PAP in the base-case analysis, which indicates that dasatinib with PAP was more cost-effective compared to thresholds applied in China ($22,455/QALY).

### Table 3

Base-case results.

| Strategy   | Imatinib 600 mg | Imatinib 800 mg | Nilotinib 800 mg | Dasatinib 100 mg |
|------------|-----------------|-----------------|-----------------|-----------------|
| PFS year   | 3.49            | 8.73            | 9.23            | 9.45            |
| LY         | 4.96            | 10.14           | 10.63           | 10.85           |
| QALY       | 2.70            | 5.75            | 6.19            | 6.34            |
| Cost, $    |                 |                 |                 |                 |
| without PAP| 176,630         | 392,151         | 407,211         | 307,715         |
| with PAP   | 74,007          | 137,199         | 141,184         | 133,866         |
| ICER, $/QALY|                |                 |                 |                 |
| without PAP| —               | 70.601          | 66.005          | 58.989          |
| with PAP   | —               | 20.701          | 19.230          | 16.417          |

ICER = incremental cost-effectiveness ratio, LY = life years, PAP = patient assistance program, PFS = progression-free survival, QALY = quality-adjusted life years.
Several previous studies have attempted to estimate the cost-effectiveness of second-generation TKIs in CML patients who are resistant to standard-dose imatinib. Ghatnekar et al. (2010) conducted an economic analysis of dasatinib versus imatinib (800mg); dasatinib was a cost-effective treatment because it offered an additional 0.62 QALY with an additional US $4,521 cost during a lifetime period, which resulted in US $7,318 per QALY gained in the Swedish healthcare system. This study used different initial responses and PFS benefits beyond the duration of the trial. In Thailand, Kulpeng et al. (2014) reported that treatment with dasatinib gained more QALYs (2.13) at a lower cost (US $46,166) and an ICER of THB US $2,358 per QALY for nilotinib compared to imatinib (800mg) strategy. In our study, dasatinib with PAP was a cost-effective strategy (consistent with the previous 2 studies), although many factors differed in our analysis, including the discount rates, background mortality rates, unit prices, and resource use. Hoyle et al. (2011) conducted an economic analysis of dasatinib and nilotinib compared to imatinib (800mg) from the perspective of the UK National Health Service. The authors found that nilotinib was better than high-dose imatinib with an additional 0.32 QALYs at a slightly lower cost (US $13,862). The authors also concluded that dasatinib provided slightly more (0.53) QALYs at a substantially greater cost (US $61,071), which yielded a very high incremental cost-effectiveness ratio of US $114,274/QALY versus high-dose imatinib. One potential reason for this finding might be the different costs of TKIs. The cost of imatinib (800mg) per day in the UK was nearly 23% higher than nilotinib and 28% higher than dasatinib. In our study, the cost of imatinib (800mg) per day was nearly 30% higher than nilotinib and 60% higher than dasatinib.

Due to the intolerance of most Chinese CML patients to imatinib (800mg), the imatinib (600mg) strategy has always been administered for CML patients who are resistant to standard-dose imatinib in Chinese clinical practices. Thus, one of the strengths of this study was the use of imatinib (600mg) as a baseline strategy in contrast to previous studies that utilized the imatinib (800mg) strategy. Imatinib dose escalation would notably increase the cost of drug acquisition but limit efficacy.

This study identified the most beneficial baseline strategy for assessing the cost-effectiveness of second-generation TKIs in a Chinese context. However, the observational times for these dasatinib and nilotinib trials were short, and patients with CML-CP typically survive for many years. Thus, accurately extrapolating the survival times beyond the current follow-up times would be necessary. The prognosis data used in this model was

### Table 4

| Parameters                                | Base value | Low value   | ICER        | High value  | ICER        |
|-------------------------------------------|------------|-------------|-------------|-------------|-------------|
| Median survival time after progression    | 12 months  | 6 months    | Dominates   | 24 months   | Dominates   |
| Cost of dasatinib, reduction              | 75%        | 80%         | Dominates   | 70%         | Dominates   |
| Cost of nilotinib, reduction              | 75%        | 80%         | Dominates   | 70%         | Dominates   |
| Cost of postfailure treatment             | $950       | $403        | Dominates   | $1290       | Dominates   |
| Cost of blood transfusion                 | $39        | $19         | Dominates   | $81         | Dominates   |
| Utility of chronic phase with response    | 0.84       | 0.82        | Dominates   | 0.86        | Dominates   |
| Utility of chronic phase without response | 0.66       | 0.63        | Dominates   | 0.68        | Dominates   |
| Age                                       | 43 years   | 35 years    | Dominates   | 60 years    | Dominates   |
| Discounting                               | 3%         | 0%          | Dominates   | 8%          | Dominates   |

CCyR = complete cytogenetic response, ICER = incremental cost-effectiveness ratio, PAP = patient assistance program.
derived from a study with a longer follow-up time, which was parametrized using the Weibull model.[13]

Nonetheless, the results from this analysis must be interpreted carefully within the limitations of the data and study design. First and foremost, owing to the absence of head-to-head trials for all 4 competing strategies for the second-line therapy of CML resistant to standard-dose imatinib, the clinical efficacy data used in this study were obtained from 3 different clinical trials, and an indirect comparison was conducted. Second, new therapies are rapidly being developed for managing imatinib-resistant CML, including bosutinib.[34] This approach has improved the long-term efficacy and tolerance results for patients with imatinib-resistant or imatinib-intolerant CML.[35] However, these new agents tend to be more expensive than current therapies. The current analysis did not trace all the medical resources associated with the potential new agents. Third, a relationship is assumed between PFS and initial treatment response for predicting the lifetime health outcome. However, the lifetime results in this study were derived from a relatively short-term study.[13] We also assumed that this relationship was the same for all strategies.[8] This is a common dilemma when modeling economic analyses. When more information becomes available, the analysis should be updated. Fourth, the long-term use of nilotinib would increase the risk of cardiovascular toxicity,[36,37] and the current analysis did not evaluate the impact of these toxicities. Fifth, with the approval and sales of generics, the costs of these TKIs would be decreased. However, only brand-name drugs were evaluated in the present study because the quality of Chinese generics of dasatinib and imatinib are always to be suspected and need to be further examined in Chinese clinical practice. Finally, the utility scores in current analysis were categorized based on the treatment responses, and it was assumed that utility scores for high-dose imatinib were equal to dasatinib and nilotinib. However, the incidence of adverse events in patients receiving high-dose imatinib was higher compared to dasatinib and nilotinib,[38] which affects quality of life.[39] Nonetheless, the results of the present modeling study can be used to inform health policy decisions in a Chinese context.

5. Conclusions
The high cost-effectiveness ratio of dasatinib for CML patients resistant to standard-dose imatinib is based on plausible structural assumptions when PAP is available in a Chinese setting. The most critical weakness is that our model was synthesized from a heterogeneous collection of clinical outcome data derived from studies with varying designs. The results should be explained carefully. When higher quality data become available, the results will need to be updated.

Acknowledgments
The authors would like to thank the editor and 3 anonymous reviewers for their valuable comments and suggestions to improve the manuscript.

References
[1] Apperley JF. Chronic myeloid leukaemia. Lancet 2015;385:1447–59.
[2] Wang JX, Huang XJ, Wu DP, et al. Overview of chronic myelogenous leukemia and its current diagnosis and treatment patterns in 15 hospitals in China. Zhonghua Xue Ye Xue Za Zhi 2009;30:721–5.
[3] Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758–65.
[4] Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol 2014;89:547–56.
[5] Baccarani M, Castagnetti F, Gugliotta G, et al. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol 2015;94(suppl 2):141–7.
[6] Ghamekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML),
resistant to standard dose imatinib—a Swedish model application. Acta Oncol 2010;49:851–8.

[7] Kulpeng W, Sompatak S, Jootar S, et al. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. Clin Ther 2014;36:534–43.

[8] Hoyle M, Rogers G, Moxham T, et al. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health 2011;14:1057–67.

[9] Barbieri M, Drummond M, Rutten F, et al. What do international pharmacoeconomic guidelines say about economic data transferability? Value Health 2010;13:1028–37.

[10] Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making 2012;32:690–700.

[11] Huang XJ, Hu JD, Li JY, et al. Study on efficacy and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib. Zhonghua Xue Ye Xue Za Zhi 2012;33:889–95.

[12] Pan LQ, Liu WX, Zhu Y, et al. Nilotinib treatment for patients with imatinib-resistant or intolerant chronic myeloid leukemia. Zhongguo shi yan xue ye xue za zhi 2014;22:1545–9.

[13] Shah NP, Guilford F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 2014;123:2317–24.

[14] Kantarjian H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136–47.

[15] Kantarjian HM, Giles FJ, Bhatia KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2013;117:1141–5.

[16] Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154–60.

[17] Oehler VG. Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice. Hematol Am Soc Hematol Educ Program 2013;2013:176–83.

[18] Chinese Society of Hematology CMAThe guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition). Zhonghua Xue Ye Xue Za Zhi 2016;37:633–9.

[19] Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 2007;11:1–iii, iv, ix–x, 221.

[20] Johansson B, Fliedt T, Meitzen M. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002;107:76–94.

[21] Sweet K, Zhang L, Prilla-Ibarz J. Biomarkers for determining the prognosis in chronic myelogenous leukemia. J Hematol Oncol 2013;6:54.

[22] Akwaa F, Liesveld J. Surrogate end points for long-term outcomes in chronic myeloid leukemia. Leuk Lymphoma 2013;54:2103–11.